Talis Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
18 February 2021 - 8:05AM
Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to
developing innovative molecular diagnostic tests for infectious
diseases at the point-of-care, today announced the closing of its
previously announced initial public offering of 15,870,000 shares
of its common stock, which includes 2,070,000 shares sold pursuant
to the exercise in full by the underwriters of their option to
purchase additional shares, at a price to the public of $16.00 per
share. Including the option exercise, the aggregate gross proceeds
to Talis from the offering were approximately $253.9 million,
before deducting the underwriting discounts and commissions and
offering expenses. The shares began trading on The Nasdaq Global
Market on February 12, 2021, under the ticker symbol “TLIS.”
J.P. Morgan, BofA Securities and Piper Sandler & Co. acted
as book-running managers for the offering. BTIG acted as co-manager
for the offering.
A registration statement relating to these securities has been
filed with the Securities and Exchange Commission and was declared
effective on February 11, 2021. Copies of the registration
statement can be accessed through the Securities and Exchange
Commission’s website at www.sec.gov. The offering was made only by
means of a written prospectus, forming a part of the effective
registration statement. A copy of the final prospectus relating to
the initial public offering may be obtained from: J.P. Morgan
Securities LLC, Attention: Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, NY 11717, by telephone at (866)
803-9204, or by emailing prospectus-eq_fi@jpmchase.com; BofA
Securities, Attention: Prospectus Department, NC1-004-03-43, 200
North College Street, 3rd Floor, Charlotte, NC 28255-0001, by
telephone at (800) 294-1322, or by email at
dg.prospectus_requests@bofa.com; or Piper Sandler & Co.,
Attention: Prospectus Department, 800 Nicollet Mall, J12S03,
Minneapolis, MN 55402, by telephone at (800) 747-3924, or by email
at prospectus@psc.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy, nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Talis
Talis is dedicated to transforming diagnostic testing by
developing and commercializing innovative products that are
designed to enable accurate, low cost and rapid molecular testing
for infectious diseases at the point-of-care, beginning with
COVID-19. The company is developing the Talis One, a compact,
sample-to-answer, cloud-enabled, molecular diagnostic platform.
Contact:Media & InvestorsEmily
Faucetteefaucette@talisbio.com+1.415.595.9407
Talis Biomedical (NASDAQ:TLIS)
Historical Stock Chart
From Apr 2024 to May 2024
Talis Biomedical (NASDAQ:TLIS)
Historical Stock Chart
From May 2023 to May 2024